"Inadequate Response": Suboptimal, Treatment Resistance, and Pseudo Resistance in Individuals with MDD

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Suboptimal Response in Major Depressive Disorder: What’s Next When First-Line Treatment Fails?

"Inadequate Response": Suboptimal, Treatment Resistance, and Pseudo Resistance in Individuals with MDD

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    Many patients with Major Depressive Disorder (MDD) do not adequately respond to or fail first-line antidepressant therapy causing significant setbacks in patient care and dramatic decreases in QoL. The lack of agreement on approaching the next treatment step creates a significant gap, leading to suboptimally treated MDD. Clinicians have the option to augment therapy or switch to another class of antidepressants to improve the management of a patient’s residual symptoms of MDD. This program will help highlight the appropriate treatment for individuals with MDD who are suboptimally treated and provide evidence-based best practices related to making a timely switch from a first-line to a second-line antidepressant or augmenting the current treatment option. 

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including nurse practitioners, psychiatrists, physician assistants, physicians, nurses, and pharmacists who specialize in psychiatry.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Translate scores of screening tools appropriately to confirm inadequate response to initial therapy for depression
    • Develop confidence in switching between antidepressant therapies once a patient has been identified as suboptimally treated or has failed first-line antidepressant therapy
    • Differentiate between alternative treatment options for a patient who has failed first-line antidepressant therapy
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Denise Vanacore, PhD, FNP-BC, PMHNP-BC, chair for this educational event, has no relevant financial relationships with ineligible companies. 

    Catherine Sheahan, APRN, PMHNP-BC, FNP-BC, faculty for this educational event, has no relevant financial relationships with ineligible companies. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Prerna Poojary, PhD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    Total CME, LLC. Planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Takeda Pharmaceuticals USA, Inc.

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.

  • Instructions for Completion

    During the period 7/21/2023 through 7/21/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:
    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule17 Jul 2024